American and international respondents provided insight into CBD consumer behavior
MIAMI, FL / ACCESSWIRE / July 28, 2020 / Verified CBD’s recent CBD survey saw 300 respondents provide insight into CBD consumer demographics, preferred products, and motivations for turning to CBD.
The survey found that one of the most common applications for CBD is for pain management and relief, with about 37% of respondents saying that they use CBD products for this purpose. Other common uses include improving mental health (anxiety, stress, and depression) and managing insomnia. The findings of this survey correspond with a Gallup poll conducted in 2019, which found that 40% of American CBD users look to the cannabinoid for pain relief, while 20% use it for anxiety and 11% for insomnia.
Of those surveyed, many say they rely on CBD cream for soothing aches and pains, though capsules and tinctures are also popular CBD products. Gummies are growing in popularity due to their enjoyable flavors and the ability for consumers to take them discreetly almost anywhere.
“We’re finding that customers are most concerned with the quality of the CBD they’re purchasing,” says Verified CBD founder Bob Chambers. “Nearly a quarter of our survey respondents said that this was their top concern. Consumers want to feel confident that they’re getting a high-quality product that is potent enough to provide relief from their health symptoms.”
Respondents also indicated concern regarding the efficacy of the CBD products they’re interested in and are interested in learning more about how to find the right dosage.
For more information about the CBD market, product launches, and industry developments, visit verifiedcbd.com or on social @verifiedcbd.
Media Contact:
Maria Harutyunyan
maria.verifiedcbd@gmail.com
SOURCE: Verified CBD
View source version on accesswire.com:
https://www.accesswire.com/598441/Verified-CBD-Recaps-2020-CBD-Survey-Results
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…
Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…
Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…
New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…
Data presented at the 2024 FMF (Fetal Medicine Foundation) World Congress in Lisbon, Portugal shows the…
Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…